Monica L. Lispi
Frankfurter Str. 250, F135/002
Darmstadt, HE 64293, Germany
Darmstadt, HE 64293, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications
Trafficking of luteinizing hormone receptor directs the differential signal activation between luteinizing hormone and chorionic gonadotropin.
Journal: International journal of biological macromolecules
Published: April 15, 2025
Expert opinion on refined and extended key performance indicators for individualized ovarian stimulation for assisted reproductive technology.
Journal: Fertility and sterility
Published: July 22, 2024
Analytical Investigation of the Profile of Human Chorionic Gonadotropin in Highly Purified Human Menopausal Gonadotrophin Preparations.
Journal: International journal of molecular sciences
Published: July 03, 2024
Dose accuracy of the follitropin alfa pen injector 2.0, the follitropin alfa:lutropin alfa 2:1 combination pen injector 2.0 and the choriogonadotropin alfa pen injector 1.0 used for fertility treatment.
Journal: Expert opinion on drug delivery
Published: February 01, 2024
Response to: Randomized, assessor-blinded trial comparing highly purified human menotropin and recombinant follicle-stimulating hormone in high responders undergoing intracytoplasmic sperm injection.
Journal: Fertility and sterility
Published: September 08, 2023
Effectiveness of recombinant human FSH: recombinant human LH combination treatment versus recombinant human FSH alone for assisted reproductive technology in women aged 35-40 years.
Journal: Reproductive biomedicine online
Published: July 28, 2023
Correction: Biosimilar recombinant follitropin alfa preparations versus the reference product (Gonal-F®) in couples undergoing assisted reproductive technology treatment: a systematic review and meta-analysis.
Journal: Reproductive biology and endocrinology : RB&E
Published: July 26, 2023
Withdrawal notice to: 'Effectiveness of recombinant human follicle-stimulating hormone (r-hFSH): recombinant human luteinizing hormone versus r-hFSH alone in assisted reproductive technology treatment cycles among women aged 35-40 years: A German database study' [YBEOG 89C (2023) 102350].
Journal: Best practice & research. Clinical obstetrics & gynaecology
Published: July 01, 2023
Letter to the editor in response to 'A real-world study of ART in France (REOLA) comparing a biosimilar rFSH against the originator according to rFSH starting dose' by P. Barrière, S. Hamamah, E. Arbo, C. Avril, B. Salle, J.-L. Pouly, et al. (J Gynecol Obstet Hum Reprod. 2023;52(1):102510).
Journal: Journal of gynecology obstetrics and human reproduction
Published: June 23, 2023
Follicle-Stimulating Hormone Biological Products: Does Potency Predict Clinical Efficacy?
Journal: International journal of molecular sciences
Published: March 24, 2023
Biological Assay to Determine Gonadotropin Potency: From In Vivo to In Vitro Sustainable Method.
Journal: International journal of molecular sciences
Published: March 15, 2023
Effectiveness of recombinant human follicle-stimulating hormone (r-hFSH): recombinant human luteinizing hormone versus r-hFSH alone in assisted reproductive technology treatment cycles among women aged 35-40 years: A German database study.
Journal: Best practice & research. Clinical obstetrics & gynaecology
Published: March 09, 2023
Last Updated: 09/26/2026